AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22036862
Drug: Hemoporfin 5
RxNorm normalized name: Hemoporfin
DrugBank: Hemoporfin (DB16183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoporfin 5 mg/kg
Trial: 22036862
Drug: Hemoporfin 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoporfin 7.5 mg/kg
Trial: 22036862
Drug: Hemoporfin 10
RxNorm normalized name: Hemoporfin
DrugBank: Hemoporfin (DB16183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoporfin 10 mg/kg
Trial: 17176456
Drug: NULL (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NULL (no drug treatment)
Trial: 15630643
Drug: Incisional bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incisional bupivacaine (0.5 ml/kg, 0.25% for <40 kg, 0.5% for >40 kg)
Trial: 8977510
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray (1 puff)
Trial: 3912182
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg felodipine three times a day
Trial: 3912182
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg felodipine three times a day
Trial: 24496044
Drug: Pregnenolone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnenolone (50 mg/d)
Trial: 16645372
Drug: Ibutilide pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide pretreatment (0.01 mg/kg IV over 10 min)
Trial: 1951408
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin 750 mg taken twice daily (n = 52)
Trial: 1951408
Drug: Continued parenteral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued parenteral antibiotics (n = 53)
Trial: 24374975
Drug: Single-dose vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose vemurafenib (960 mg)
Trial: 2007745
Drug: Cisapride 5
RxNorm normalized name: cisapride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 5 mg t.i.d. for 12 weeks
Trial: 6122970
Drug: Once-monthly rifampicin
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once-monthly rifampicin (1,200 mg in a single oral dose) plus daily dapsone (50 mg/day)
Trial: 6122970
Drug: Daily rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily rifampicin (450 mg/day) plus daily dapsone (50 mg/day)
Trial: 6122970
Drug: Once-monthly rifampicin
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once-monthly rifampicin (1,200 mg in a single oral dose)
Trial: 6122970
Drug: Daily rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily rifampicin (450 mg/day)
Trial: 21514398
Drug: Bimosiamose (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimosiamose (10 mg bid)
Trial: 16921033
Drug: Early thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early thoracic radiotherapy (TRT) administered concurrently in the second cycle
Trial: 16921033
Drug: Late thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late thoracic radiotherapy (TRT) administered concurrently with the sixth cycle
Trial: 12835516
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (doxorubicin + DES)
Trial: 2059673
Drug: Olsalazine (OLZ)
DrugBank: Olsalazine (DB01250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olsalazine (OLZ) tablets (1g)
Trial: 2059673
Drug: Olsalazine (OLZ)
DrugBank: Olsalazine (DB01250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olsalazine (OLZ) capsules (1g)
Trial: 6366141
Drug: Alternating combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating combination chemotherapy (vincristine, doxorubicin, alkylating agents, and prednisone)
Trial: 6366141
Drug: Alternating combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating combination chemotherapy
Trial: 6366141
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy with levamisole
Trial: 6366141
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy (melphalan and prednisone)
Trial: 26417061
Drug: 90-day use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90-day use of Vaughan Williams class I or III antiarrhythmic drugs (AAD)
Trial: 24614387
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (4000 IU/day of vitamin D3 plus a daily multivitamin containing 400 IU of vitamin D3)
Trial: 19175929
Drug: AVI-014 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVI-014 at 4 mcg/kg
Trial: 19175929
Drug: AVI-014 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVI-014 at 8 mcg/kg
Trial: 19175929
Drug: filgrastim (Neupogen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: filgrastim (Neupogen, Amgen) at 4 mcg/kg
Trial: 19175929
Drug: filgrastim (Neupogen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: filgrastim (Neupogen, Amgen) at 8 mcg/kg
Trial: 17984247
Drug: Flutamide-metformin (62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide-metformin (62.5 mg/day + 850 mg/day)
Trial: 17984247
Drug: Metformin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin alone (850 mg/day)
Trial: 8887604
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 100 microg administered twice a day via a Diskhaler for 3 months
Trial: 28623628
Drug: Software-based preference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Software-based preference assessment in addition to the brochure about prostate cancer treatment
Trial: 28623628
Drug: Education with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education with a brochure about prostate cancer treatment
Trial: 25487185
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of toluidine blue with micropipette followed by 630-nm GaAlAs laser (power density: 10 mW/cm²) during two visits
Trial: 25487185
Drug: Mouthwash diluted
RxNorm normalized name: phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mouthwash diluted with dexamethasone (tab 0/5 in 5 ml water) for 5 min, followed by rinsing with nystatin 100,000 units for 5 min
Trial: 24010987
Drug: 4% prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% prilocaine plain, 5 mg/kg
Trial: 24010987
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 1:100,000 epinephrine, 2.5 mg/kg
Trial: 21396408
Drug: Intranasal trivalent
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal trivalent live attenuated influenza vaccine (LAIV)
Trial: 21396408
Drug: Intramuscular trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular trivalent inactivated vaccine (TIV)
Trial: 16485884
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide 5%/clindamycin phosphate 1% gel with dimethicone and glycerin
Trial: 16485884
Drug: Combination use
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination use with topical retinoid
Trial: 11534890
Drug: Budesonide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (100 microg or 400 microg) twice daily plus formoterol 9 microg twice daily
Trial: 11534890
Drug: Budesonide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (100 microg or 400 microg) twice daily
Trial: 9324366
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml of prilocaine 1%
Trial: 9324366
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of prilocaine 1% plus 10 ml bupivacaine 0.5%
Trial: 9324366
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of prilocaine 1% plus 20 ml bupivacaine 0.5%
Trial: 2881572
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg ethyl loflazepate
Trial: 2881572
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg ethyl loflazepate
Trial: 15920748
Drug: Usual diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual diet plus supplements (group 2)
Trial: 7749435
Drug: 252 mg
RxNorm normalized name: menthol 0.0252 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 252 mg quinacrine pellets
Trial: 7749435
Drug: 324 mg
RxNorm normalized name: aspirin 324 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 324 mg quinacrine pellets
Trial: 7749435
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg quinacrine (previously reported)
Trial: 1703909
Drug: rh-EPO at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rh-EPO at a dose of 3 x 80 U/kg body weight per week
Trial: 26445924
Drug: Rosuvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin treatment for 18 months
Trial: 23863036
Drug: Less oxidized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less oxidized omega-3 oil pills
Trial: 23863036
Drug: Highly oxidized
RxNorm normalized name: Ferrosoferric Oxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highly oxidized omega-3 oil pills
Trial: 23863036
Drug: No capsules
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No capsules (control group)
Trial: 18665696
Drug: Monitoring Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring Group (MG)
Trial: 12866115
Drug: Optimal cardiac
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal cardiac medication (controls)
Trial: 9168460
Drug: Menhaden oil
RxNorm normalized name: MENHADEN OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menhaden oil (6.26 g, n-3 fatty acids) with vitamin E (900 IU)
Trial: 9168460
Drug: Menhaden oil
RxNorm normalized name: MENHADEN OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menhaden oil (6.26 g, n-3 fatty acids)
Trial: 9168460
Drug: Menhaden oil
RxNorm normalized name: MENHADEN OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menhaden oil (6.26 g, n-3 fatty acids) with placebo instead of vitamin E
Trial: 1550166
Drug: Subcutaneous terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous terbutaline pump
Trial: 30808668
Drug: 21 mg
RxNorm normalized name: aspirin 421 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 mg nicotine patches + 18 mg/mL nicotine e‐cigarette
Trial: 30808668
Drug: 21 mg
RxNorm normalized name: aspirin 421 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 mg nicotine patches + nicotine free e‐cigarette
Trial: 29521661
Drug: Spinal anaesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anaesthesia with 40-mg chloroprocaine 1%
Trial: 27354234
Drug: Packaged Cognitive‐Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Packaged Cognitive‐Behavioral Treatment (PCBT)
Trial: 23075518
Drug: NeuroFlo™ device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NeuroFlo™ device treatment
Trial: 12743579
Drug: Celecoxib (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (10, 30, or 100 mg in suspension)
Trial: 12743579
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg administered as two 200-mg doses 2 hours apart)
Trial: 9295819
Drug: Somatostatin (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (3.5 micrograms/kg, 20‐mL bolus) followed by continuous infusion (3.5 micrograms/kg/hr) for 72 hrs
Trial: 9295819
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (20‐mL bolus) followed by continuous infusion (20 mL for 30 mins)
Trial: 2617153
Drug: Bendroflumethiazide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendroflumethiazide (2.5 mg o.d.)
Trial: 31202508
Drug: Ibuprofen acid
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen acid orodispersible tablets (Test product)
Trial: 31202508
Drug: Ibuprofen acid
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen acid oral tablets (Reference product)
Trial: 31202508
Drug: Ibuprofen S(+)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen S(+) and R(−) enantiomers
Trial: 29395273
Drug: Cannabidiol 20
RxNorm normalized name: CANNABIDIOL 20 g in 100 mL ORAL OIL [leafPro CBDmed Oil FS QP 20%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol 20 mg/kg oral daily for 14 weeks
Trial: 25148049
Drug: Azithromycin 250
RxNorm normalized name: azithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 250 mg daily for 12 weeks
Trial: 20101593
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral carbohydrate (OCH)
Trial: 18807578
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of omeprazole (20 mg)
Trial: 12823078
Drug: Morning light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning light therapy (30 minutes of 400 lux green light treatment)
Trial: 12823078
Drug: Citalopram (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (40 mg) with morning light therapy
Trial: 12823078
Drug: Citalopram (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (40 mg) with placebo (deactivated negative ion generator)
Trial: 9100603
Drug: 5 alpha-dihydrotestosterone
RxNorm normalized name: 5.alpha.-hydroxy laxogenin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 alpha-dihydrotestosterone (DHT; 7.0 mg/day)
Trial: 8448069
Drug: alpha MeHA,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha MeHA, 10 mg (as a chloride salt)
Trial: 3768929
Drug: 2.5 mg/day
RxNorm normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/day of metolazone
Trial: 16428156
Drug: 12% salicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12% salicylic acid gel
Trial: 1907241
Drug: Intracoronary streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary streptokinase (thrombolytic therapy)
Trial: 6809158
Drug: Heat-stable measles
RxNorm normalized name: (9-L-TYROSINE)HEAT-STABLE ENTEROTOXIN (ESCHERICHIA COLI)-(6-19)-PEPTIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-stable measles vaccine; stored unreconstituted at 37 degrees C for 14 days
Trial: 6809158
Drug: Heat-stable measles
RxNorm normalized name: (9-L-TYROSINE)HEAT-STABLE ENTEROTOXIN (ESCHERICHIA COLI)-(6-19)-PEPTIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-stable measles vaccine; reconstituted and stored at 25 degrees C for 48 hours and at 37 degrees C for at least four hours
Trial: 6809158
Drug: Conventional measles
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional measles vaccines
Trial: 28683994
Drug: Intravenous methylprednisolone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone, 250 mg at anesthetic induction and 250 mg at initiation of CPB (n=44)
Trial: 25712416
Drug: High-dose atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose atorvastatin (80 mg the day before PCI and 40 mg 2-4 h before PCI)
Trial: 25712416
Drug: Low-dose statins
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose statins
Trial: 23811624
Drug: Ultrasound-guided caudal
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided caudal block with 8 ml of 0.3% ropivacaine and 100 µg of fentanyl
Trial: 22066975
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (n = 40) performing daily exercise with weekly load increase for 3 months
Trial: 18271691
Drug: Low-calorie diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calorie diet (LCD) with yogurt enriched by low doses of n-3 PUFA (n-3 LCD)
Trial: 9351414
Drug: Vaginal prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal prostaglandin (PG) (PGE1, gemeprost 1 mg) preoperatively + GA
Trial: 9351414
Drug: Vaginal prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal prostaglandin (PG) (PGE1, gemeprost 1 mg) preoperatively + GA + PCB
Trial: 9351414
Drug: GA without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GA without PG treatment
Trial: 9351414
Drug: Vaginal prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal prostaglandin (PG) (PGE1, gemeprost 1 mg) preoperatively
Trial: 30518237
Drug: Oral language
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral language training
Trial: 25767372
Drug: rosuvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin (20 mg/day) + valsartan (160 mg/day)
Trial: 18441375
Drug: Nortriptyline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline plus nicotine replacement therapy
Trial: 18441375
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus nicotine replacement therapy
Trial: 25749306
Drug: Nortriptyline-Morphine Combination
RxNorm normalized name: morphine, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline-Morphine Combination
Trial: 19929666
Drug: Subcutaneous infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous infiltration of local anaesthetic
Trial: 17180619
Drug: L: ‐tryptophan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L: ‐tryptophan (Trp)
Trial: 9644320
Drug: TAT-59 (miproxifene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAT-59 (miproxifene phosphate) 20 mg orally for over 12 weeks
Trial: 9644320
Drug: Tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen citrate (TAM) 20 mg orally for over 12 weeks
Trial: 8159440
Drug: Hyperglycemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemia (blood glucose elevated to 12 mmol/l for 0.5 h and kept at that level for 2.5 h)
Trial: 8159440
Drug: Euglycemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycemia (blood glucose kept at 6 mmol/l for 3 h)
Trial: 30256811
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose vitamin D (10,000 IU/day)
Trial: 30256811
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose vitamin D (10,000 IU/day) in younger participants (ages 52-66)
Trial: 27178513
Drug: Intratympanic dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratympanic dexamethasone (ITD) plus high dosage of betahistine (HDBH)
Trial: 22430270
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of TET2(mut) and/or IDH(mut)
Trial: 20332125
Drug: Omnitrope 3.3
RxNorm normalized name: Omnitrope 3.3 MG/ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omnitrope 3.3 mg/ml solution
Trial: 20332125
Drug: Omnitrope 6.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omnitrope 6.7 mg/ml solution
Trial: 20332125
Drug: Omnitrope 5
RxNorm normalized name: Omnitrope 5 Pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omnitrope 5 mg/ml powder
Trial: 20332125
Drug: Genotropin 5
RxNorm normalized name: Genotropin 5 MG/ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotropin 5 mg/ml powder
Trial: 15659145
Drug: Everolimus 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 3.0 mg/d